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OBJECTIVES The aim of this study was to evaluate the survival of patients with hypertrophic cardiomy-
opathy (HCM) after resuscitated ventricular fibrillation or syncopal sustained ventricular
tachycardia (VT/VF) when treated with low dose amiodarone or implantable cardioverter
defibrillators (ICDs).
BACKGROUND Prospective data on clinical outcome in patients with HCM who survive a cardiac arrest are
limited, but studies conducted before the widespread use of amiodarone and/or ICD therapy
suggest that over a third die within seven years from sudden cardiac death or progressive heart
failure.
METHODS Sixteen HCM patients with a history of VT/VF (nine male, age at VT/VF 19 6 8 years
[range 10 to 36]) were studied. Syncopal sustained ventricular tachycardia/ventricular
fibrillation occurred during or immediately after exertion in eight patients and was the initial
presentation in eight. One patient had disabling neurologic deficit after VT/VF. Before
VT/VF, two patients had angina, four had syncope and six had a family history of premature
sudden cardiac death. After VT/VF all patients were in New York Heart Association class I
or II, three had nonsustained VT during ambulatory electrocardiography and 11 had an
abnormal exercise blood pressure response. After VT/VF eight patients were treated with low
dose amiodarone and six received an ICD. Prophylactic therapy was declined by two patients.
RESULTS Mean follow-up was 6.1 6 4.0 years (range 0.5 to 14.5). Cumulative survival (death or ICD
discharge) for the entire cohort was 59% at five years (95% confidence interval: 33% to 84%).
Thirteen (81%) patients were alive at last follow-up. Two patients died suddenly while taking
low dose amiodarone, and one died due to neurologic complications of his initial cardiac
arrest. Three patients had one or more appropriate ICD discharges during follow-up; the
times to first shock after ICD implantation were 23, 197 and 1,124 days.
CONCLUSIONS This study shows that patients with HCM who survive an episode of VT/VF remain at risk
for a recurrent event. Implantable cardioverter defibrillator therapy appears to offer the best
potential benefit regarding outcome. (J Am Coll Cardiol 1999;33:1596–601) © 1999 by the
American College of Cardiology
Hypertrophic cardiomyopathy (HCM) is a primary cardiac
muscle disorder caused by mutations in genes encoding
cardiac sarcomeric proteins (1). Sudden death, its most
important complication, is reported to occur with an annual
incidence of 2% to 4% in tertiary referral centers (2,3), and
approximately 1% in predominantly regionally based popu-
lations (4–6). A relatively low annual event rate, and the
fact that most patients with HCM fail to survive their first
episode of ventricular fibrillation, mean that prospective
studies of clinical outcome in patients who survive a cardiac
arrest are scarce. The data that are available suggest that
over a third of patients experience a further cardiac arrest or
die from progressive heart failure within seven years when
treated in a nonsystematic fashion (7). The aim of this study
was to determine whether treatment with low dose amio-
darone and/or implantable cardioverter defibrillators (ICDs)
has improved clinical outcome in HCM patients who have
survived a cardiac arrest or syncopal ventricular tachycardia.
METHODS
Patients. Sixteen patients (nine male) referred between
1988 and 1997 with a history of witnessed sudden cardio-
vascular collapse in association with documented ventricular
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fibrillation or syncopal sustained ventricular tachycardia
(VT/VF) requiring direct current cardioversion were stud-
ied. These patients were recruited from a larger series of 630
patients referred during the same period. Fourteen had a
history of VT/VF before their first assessment at our
institution, and one afterwards. The initial assessment of
Patient 15 was performed at another hospital within the
United Kingdom, but all his clinical data were reviewed by
the authors, and other members of his family are under
follow-up at our institution. To date, single amino acid
substitutions in genes encoding sarcomeric protein muta-
tions have been identified in six patients; beta-myosin heavy
chain gene mutations in two patients (Arg719Trp and
Arg453Cys) and cardiac troponin T mutations in four
(Arg92Glu, Arg278Cys and Ile79Asn) (8–11). Three other
patients have been screened for beta-myosin heavy chain
and troponin T mutations with negative results. The results
of genetic screening in the remaining seven patients are
awaited.
Clinical evaluation. Two dimensional and M-mode echo-
cardiography were performed using conventional techniques
(12,13). Left ventricular wall thickness was recorded, where
possible, at mitral valve and papillary muscle level in the
anterior and posterior septum, and in the lateral and
posterior left ventricular walls using short-axis two-
dimensional images. Anterior and posterior wall thickness
at the apex was measured in the four-chamber apical view.
In 15 patients the diagnosis of HCM was based on the
demonstration of a maximum left ventricular wall thickness
greater than or equal to two standard deviations from the
normal corrected for age and body surface area in the
absence of any other cardiac or systemic cause of left
ventricular hypertrophy (14). The remaining patient had
nondiagnostic electrocardiographic and echocardiographic
abnormalities, a family history of HCM and a troponin T
mutation (Ile79Asn). Left ventricular outflow tract veloci-
ties were determined using continuous wave Doppler, and
left ventricular outflow tract gradients were calculated using
the modified Bernoulli equation.
All patients underwent 48-h ambulatory electrocardio-
graphic monitoring while performing unrestricted daily
activities using the Marquette (Marquette Electronics, Di-
agnostic Division, Milwaukee, Wisconsin) Holter recording
system on two channels. Computer-assisted analysis was
performed using the Marquette Series 8000 Laser Holter
and Laser Holter XP system. Nonsustained ventricular
tachycardia was defined as a run of three or more consecu-
tive beats at a rate of 120 beats per minute or more.
Fourteen patients underwent symptom-limited maximal
exercise testing using the Bruce or modified Bruce proto-
cols, with simultaneous respiratory gas analysis by a dedi-
cated metabolic cart (Marquette Electronics) and a mass
spectrophotometric gas analyzer according to established
methodology (15). Blood pressure was measured using a
mercury sphygmomanometer and auscultation of the
Korotkov sounds over the brachial artery at rest, every
minute during exercise and every 15 s during the initial
5 min of the recovery period. Blood pressure responses were
classified as normal, flat (i.e., a systolic blood pressure rise of
less than 20 mm Hg above the resting value during the
whole exercise period) or hypotensive (a continuous fall
throughout exercise of .20 mm Hg from baseline or an
initial increase in systolic blood pressure with a subsequent
fall of .20 mm Hg compared with the peak pressure) (16).
Follow-up. Follow-up data were obtained at regular visits
to our institution and/or by direct communication with the
patients and their attending physicians.
RESULTS
Clinical presentation. Mean age at VT/VF was 19 6 8
years (range 10 to 36). Syncopal sustained ventricular
tachycardia/ventricular fibrillation occurred during or im-
mediately after moderate to severe physical exertion in eight
patients and was the initial presentation in eight patients.
Before VT/VF, 4 (25%) patients had experienced syncope,
and 2 (13%) had exertional chest pain. Six patients (38%)
had a family history of hypertrophic cardiomyopathy and
premature (,40 years) sudden death (Table 1). Following
VT/VF 15 patients were in New York Heart Association
functional class I and II. Patient 9 had disabling neurologic
deficit after VT/VF and was confined to a wheelchair.
Evaluation after VT/VF revealed that three patients (19%)
had nonsustained VT during 48-h ambulatory electrocar-
diographic monitoring. One patient had seven runs; the
remaining two patients had two runs each. The maximum
number of beats in any run was five, and the maximum rate
was 180 beats/min. Fourteen patients underwent symptom-
limited exercise testing; 11 (79%) of the 14 had an abnormal
blood pressure response.
Echocardiography. Follow-up echocardiograms per-
formed at our institution were available in 10 of the 16
patients. The mean interval between the first and last
echocardiogram was 4.7 6 2.9 years (range 1.7 to 11.0).
Mean left ventricular end-diastolic and end-systolic diam-
eters, and maximal left ventricular wall thickness at initial
echocardiogram were 45 6 6 mm, 28 6 5 mm and 20 6
6 mm respectively. Three patients had resting left ventric-
ular outflow tract gradients of more than 30 mm Hg, two
more than 60 mm Hg. At last follow-up, mean left
ventricular end-diastolic and end-systolic diameters, and
Abbreviations and Acronyms
HCM 5 hypertrophic cardiomyopathy
ICD 5 implantable cardioverter defibrillator
VT/VF 5 syncopal sustained ventricular
tachycardia/ventricular fibrillation
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maximal left ventricular wall thickness were 49 6 6 mm,
31 6 6 mm and 18 6 3 mm respectively (p 5 NS compared
with first study). In five patients, there was a reduction of
more than 15% in maximal left ventricular wall thickness. In
three of these five patients, wall thinning was accompanied
by a .10% increase in left ventricular end-diastolic and
end-systolic cavity dimensions. In one of the five patients
there was an increase in only end-systolic dimension.
Changes in left ventricular dimensions were not associated
with a change in functional class.
Treatment. The choice of treatment related to failure of
low dose amiodarone therapy, availability of appropriate
devices and individual patient preference. After VT/VF,
eight patients were commenced on low dose amiodarone
(200 to 300 mg daily). Six patients underwent implantation
of an automatic cardioverter defibrillator. One patient who
was taking low dose amiodarone at the time of his first
cardiac arrest (Patient 11) received an ICD and discontin-
ued the drug. Two patients declined any prophylactic
therapy. No patient in this study underwent septal myotomy–
myectomy, dual chamber pacemaker insertion or transcoro-
nary alcohol ablation.
Survival. Mean follow-up from the first documented epi-
sode of VT/VF was 6.1 6 4.0 years (range 0.5 to 14.5).
Thirteen patients (81%) were alive at last follow-up. The
five-year event-free survival (death or ICD discharge) was
59% (95% confidence interval: 33% to 84%) (Fig. 1). Two
patients died while taking amiodarone; Patient 15 died
suddenly three months after starting low dose amiodarone;
Patient 10 died 1.6 years after VT/VF. Plasma levels before
death were unavailable in both patients. Plasma levels in the
remaining patients at last follow-up were 0.7 6 0.4 mg/liter.
Patient 9 died due to neurologic complications of his initial
cardiac arrest.
Of the six patients with ICDs, three (Patients 4, 8 and
11) had appropriate discharges for ventricular tachycardia or
ventricular fibrillation. The times to first discharge after
ICD implantation were 197, 1,124 and 23 days, respec-
tively. Interrogation of the ICDs in two patients demon-
strated several episodes of atrial fibrillation degenerating
into polymorphic VT (Patient 11) and sinus tachycardia
followed by ventricular tachycardia (Patient 4) (Fig. 2).
Electrocardiographic recordings were unobtainable in the
third patient but the recorded R-R intervals before the ICD
discharge were most consistent with rapid VT degenerating
into VF. One further patient (Patient 7) had a discharge for
Figure 1. Cumulative survival (Kaplan-Meier analysis) from initial
episode of syncopal sustained ventricular tachycardia/ventricular
fibrillation to death or first appropriate implantable cardioverter
defibrillator discharge. The numbers in parentheses refer to the
number of patients followed for any given time period.







BP NSVT Amiodarone ICD
1 MHC Arg435Cys 10 1 2 1 1 1 2 1 2
2 TNT Arg92Glu 16 1 2 1 2 1 2 2 2
3 12 2 2 2 2 1 2 1 2
4 TNT Arg92Glu 12 1 2 1 1 1 1 2 1
5 TNT Arg278Cys 23 2 2 1 1 2 2 2 1
6 18 2 2 1 2 1 2 1 2
7 MHC Arg719Trp 16 2 2 2 2 1 2 2 1
8 19 2 2 1 1 1 2 2 1
9 10 2 2 1 2 nd 2 2 2
10 25 2 2 1 2 1 1 1 2
11 29 2 2 1 2 2 1 2 1
12 36 2 2 2 2 2 2 1 2
13 30 1 2 2 2 1 2 1 2
14 15 2 1 2 2 1 2 2 1
15 TNT Ile79Asn 16 1 2 1 2 nd 2 1 2
16 14 1 1 1 2 1 2 1 2
Abn BP 5 abnormal exercise blood response; Arg 5 arginine; Asn 5 asparagine; CP 5 chest pain; Cys 5 cysteine; FHSD 5 family history of premature sudden death; Glu 5
Glutamine; ICD 5 implantable cardioverter defibrillator; Ile 5 isoleucine; MHC 5 beta-myosin heavy chain; nd 5 not done; NSVT 5 nonsustained ventricular tachycardia;
NYHA 5 New York Heart Association functional classification; TNT 5 troponin T; Trp 5 tryptophan; VT/VF 5 syncopal sustained ventricular tachycardia or ventricular
fibrillation.
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previously undocumented atrioventricular nodal reentry
tachycardia.
DISCUSSION
This study demonstrates that approximately 30% of patients
with HCM and a history of cardiac arrest have a further
event within six years of their first episode. It shows that
ICD therapy is an effective prophylactic treatment in such
patients, and that ICD therapy is probably superior to low
dose amiodarone in this high risk cohort. The cumulative
event-free survival of 59% at five years is very similar to that
reported in the largest series published in the pre-ICD era
by Cecchi et al. (7). However, there were a large number of
heart failure deaths in the earlier series compared with none
in this report. Patients in the earlier cohort differed from
those in the present study in that they were older, had more
severe hypertrophy and had a higher prevalence of left
ventricular outflow tract obstruction (Table 2). These clin-
ical and morphologic differences may explain the lack of
progressive heart failure deaths in the present study, al-
though the fact that some patients in our cohort did develop
progressive wall thinning despite a maintained functional
class suggests that progressive myocardial dysfunction may
be a consequence of cardiac arrest in some patients.
Markers of sudden death risk. Several clinical features are
associated with an increased risk of dying suddenly in
patients with HCM (1,2,17–19). In the young, one of the
most important is unexplained syncope (2), and this was a
prominent symptom in a quarter of the patients in the
present study. Syncope can be caused by supraventricular
arrhythmia or self-terminating ventricular tachycardia, but
in most individuals its cause is difficult to determine.
Approximately 25% of patients with HCM have abnormal
peripheral vascular responses in association with flat or
hypotensive blood pressure profiles during exercise (16,19),
and this may in some individuals predispose to syncope or
presyncope. The mechanism of abnormal peripheral vascu-
Figure 2. Stored electrocardiograms retrieved from the implanted cardioverter defibrillator (25 mm/s) showing episodes of polymorphic
ventricular tachycardia preceded by (A) atrial fibrillation (Patient 11) and (B) sinus tachycardia (Patient 4). Both episodes were successfully
terminated by maximum energy direct current shock.
Table 2. Comparative Clinical and Echocardiographic Data in
the Present Study Compared With That in a Previously
Published Series
Cecchi et al. (7) Present Study
Age (yr) 32 (9–62) 19 (10–36)
FHSD 10 (30%) 6 (38%)
Mild/no symptoms 22 (67%) 14 (77%)
Syncope 4 (12%) 4 (25%)
LVWT (mm) 28 (18–40)* 20 (9–31)
Gradient (mm Hg)† 16 2
*Seven greater than 30 mm. †Number of patients with resting left ventricular outflow
tract gradient greater than 60 mm Hg.
FHSD 5 family history of premature sudden death; LVWT 5 maximum left
ventricular wall thickness.
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lar responses remains uncertain, the most popular theory
being a centrally mediated dilation of peripheral resistance
vessels triggered by activation of ventricular mechanorecep-
tors (20). The importance of the abnormal vascular response
has recently been underlined by the demonstration of an
association with reduced survival in patients less than 40
years old (19), and it is of note that 11 of the 14 patients
who were exercised in the present study had either flat or
hypotensive blood pressure responses.
A family history of sudden death is another important
risk factor in the young (2). Several “high risk” mutations in
genes encoding a number of cardiac sarcomeric proteins are
described, and the six patients who were genotyped in this
study all had point mutations that are associated with a high
incidence of premature sudden death (1,8–11).
In adult patients, nonsustained ventricular tachycardia
during ambulatory electrocardiographic monitoring is asso-
ciated with an increased risk of sudden death (17,18), but its
significance in children and adolescents has been difficult to
determine, as it occurs much less frequently. Recently
presented data indicate that young patients with nonsus-
tained VT may be at greater risk (21), and it is notable that
the three patients in this study with nonsustained VT were
less than 40 years old. Nevertheless, further prospective
studies are required to examine the relation between specific
characteristics of nonsustained ventricular tachycardia and
survival.
Triggers for sudden cardiac death. As death in patients
with hypertrophic cardiomyopathy is by its very nature
unpredictable, the electrocardiographic events immediately
preceding cardiac arrest are rarely recorded (22,23). The
data storage facility of most modern ICDs now makes it
possible to record such events, and device interrogation in
patients who received shocks in the present study revealed
that ventricular fibrillation was preceded by atrial fibrilla-
tion, sinus tachycardia and ventricular tachycardia. This
observation is consistent with the hypothesis that ventricular
fibrillation in patients with HCM and an appropriate
arrhythmogenic substrate can be triggered by other tachy-
arrhythmias. The mechanism by which they do so is
uncertain, but accessory pathways, myocardial ischemia and
abnormal vascular responses may play a role in some
patients (1).
Low dose amiodarone versus ICD. In the present study,
similar numbers of patients were treated with low dose
amiodarone and ICDs. The number of patients studied is
too small to make definitive recommendations for therapy,
but the fact that two patients had VT/VF while taking low
dose amiodarone indicates that in the modern era, patients
with hypertrophic cardiomyopathy who survive a cardiac
arrest should be preferentially treated with an ICD. The
event rate after cardiac arrest in this study is consistent with
other recently published series that have demonstrated
appropriate ICD shocks in 15% to 25% of patients with a
history of aborted sudden death or sustained ventricular
tachycardia followed for a mean period of 2 to 4 years
(24–28). Whether ICDs can be advocated in patients who
are deemed to be “at risk” but have not yet experienced
VT/VF is less certain. To date, low dose amiodarone is the
only prophylactic therapy that has been tested in high risk
patients without a history of sudden cardiac death (29,30).
In a study of two consecutive age- and gender-matched
populations with nonsustained ventricular tachycardia (29),
patients treated with low dose amiodarone therapy had a
significantly lower sudden death rate than patients treated
with “conventional” antiarrhythmics (predominantly diso-
pyramide). A later study (30) demonstrated increased mor-
tality in patients treated with amiodarone, but the patients
in this series had very severe functional limitation and were
treated with much higher doses. Preliminary observational
data from our own patient cohort recruited over 10 years
suggest that low dose amiodarone therapy is associated with
a substantial reduction in sudden death rates in patients
with multiple risk factors (31).
Study limitations. The small size of the patient cohort in
this study is an inevitable consequence of the fact that very
few patients with HCM survive a cardiac arrest or syncopal
ventricular tachycardia. Conclusions regarding therapy in
this high risk cohort remain speculative, but in the context
of the growing number of similar reports it seems reasonable
to advocate ICD therapy in this high risk subset of patients.
Conclusions. This study shows that patients with HCM
who survive an episode of VT/VF remain at risk for a
recurrent event. Implantable cardioverter defibrillator ther-
apy appears to offer the best potential benefit regarding
outcome. The optimal treatment regimen for those patients
who are at risk but have not yet experienced a catastrophic
cardiac event requires further evaluation.
Acknowledgments
We would like to thank Sue Jones, Shaughan Dickie and
Annie O’Donoghue for their assistance with this report.
Reprint requests and correspondence: Dr. P. M. Elliott, De-
partment of Cardiological Sciences, St. George’s Hospital Medical
School, Cranmer Terrace, London SW17 0RE, United Kingdom.
REFERENCES
1. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management
of hypertrophic cardiomyopathy. N Engl J Med 1997;336:775–85.
2. McKenna WJ, Deanfield J, Faruqui A, England D, Oakley C,
Goodwin J. Prognosis in hypertrophic cardiomyopathy. Role of age
and clinical, electrocardiographic and haemodynamic features. Am J
Cardiol 1981;47:532–8.
3. McKenna WJ, Franklin RCG, Nihoyannopoulos P, Robinson KC,
Deanfield JE. Arrhythmia and prognosis in infants, children and
adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol
1988;11:147–53.
4. Spirito P, Chiarella F, Carratino L, Zoni-Berisso M, Bellotti P,
Vecchio C. Clinical course and prognosis of hypertrophic cardiomy-
opathy in an outpatients population. N Engl J Med 1989;320:749–55.
5. Cecchi F, Olivotto I, Montereggi A, Santoro G, Dolara A, Maron
BJ. Hypertrophic cardiomyopathy in Tuscany: clinical course and
1600 Elliott et al. JACC Vol. 33, No. 6, 1999
Sudden Death in Hypertrophic Cardiomyopathy May 1999:1596–601
outcome in an unselected regional population. J Am Coll Cardiol
1995;26:1529–36.
6. Cannan CR, Reeder GS, Bailey KR, Melton LJ, Gersh BJ. Natural
history of hypertrophic cardiomyopathy. A population based study,
1976 through 1990. Circulation 1995;92:2488–95.
7. Cecchi F, Maron BJ, Epstein SE. Long-term outcome of patients with
hypertrophic cardiomyopathy successfully resuscitated after cardiac
arrest. J Am Coll Cardiol 1989;13:1283–8.
8. Anan R, Greve G, Thierfelder L, et al. Prognostic implications of
novel beta cardiac myosin heavy chain gene mutations that cause
familial hypertrophic cardiomyopathy. J Clin Invest 1994;93:280–5.
9. Watkins H, McKenna WJ, Thierfelder L, et al. Mutations in the
genes for cardiac troponin T and alpha-tropomyosin in hypertrophic
cardiomyopathy. N Engl J Med 1995;332:1058–64.
10. Watkins H, Rosenzweig A, Hwang DS, et al. Characteristics and
prognostic implications of myosin missense mutations in familial
hypertrophic cardiomyopathy. N Engl J Med 1992;326:1108–14.
11. Thierfelder L, Watkins H, MacRae C, et al. Alpha-tropomyosin and
cardiac troponin T mutations cause familial hypertrophic cardiomy-
opathy: a disease of the sarcomere. Cell 1994;77:701–12.
12. Shapiro LM, McKenna WJ. Distribution of left ventricular hypertro-
phy in hypertrophic cardiomyopathy: a two dimensional echocardio-
graphic study. J Am Coll Cardiol 1983;2:437–44.
13. Maron BJ, Gottdiener JS, Epstein SE. Patterns and significance of
distribution of left ventricular hypertrophy in hypertrophic cardiomy-
opathy. A wide angle, two dimensional echocardiographic study of 125
patients. Am J Cardiol 1981;48:418–28.
14. Report of the 1995 World Health Organization/International Society
and Federation of Cardiology task force on the definition and
classification of cardiomyopathies. Circulation 1996;93:841–2.
15. Chikamori T, Counihan PJ, Doi YL, et al. Mechanisms of exercise
limitation in hypertrophic cardiomyopathy. J Am Coll Cardiol 1992;
19:507–12.
16. Frenneaux MP, Counihan PJ, Caforio A, Chikamori T, McKenna
WJ. Abnormal blood pressure response during exercise in hypertrophic
cardiomyopathy. Circulation 1990;82:1995–2002.
17. McKenna WJ, England D, Doi Y, Deanfield JE, Oakley CM,
Goodwin JF. Arrhythmia in hypertrophic cardiomyopathy. 1. Influ-
ence on prognosis. Br Heart J 1981;46:168–72.
18. Maron BJ, Savage DD, Wolfson JK, Epstein SE. Prognostic signifi-
cance of 24 hour ambulatory electrocardiographic monitoring in
patients with hypertrophic cardiomyopathy: a prospective study. Am J
Cardiol 1981;48:252–7.
19. Sadoul N, Prasad K, Elliott PM, Banerjee S, Frenneaux MP,
McKenna WJ. Prospective prognostic assessment of blood pressure
response during exercise in patients with hypertrophic cardiomyopa-
thy. Circulation 1997;96:2987–91.
20. Counihan PJ, Frenneaux MP, Webb DJ, McKenna WJ. Abnormal
vascular responses to supine exercise in hypertrophic cardiomyopathy.
Circulation 1991;84:686–96.
21. Monseratt L, Elliott P, Prasad K, Penas-Lado M, Castro-Beiras A,
McKenna WJ. Non-sustained ventricular tachycardia and sudden
death in hypertrophic cardiomyopathy (abstr). J Am Coll Cardiol
1998;31 Suppl:26A.
22. Stafford WJ, Trohman RG, Bilsker M, Zaman L, Catellanos A,
Myerburg RJ. Cardiac arrest in an adolescent with atrial fibrillation
and hypertrophic cardiomyopathy. J Am Coll Cardiol 1986;7:
701– 4.
23. Nicod P, Polikar R, Peterson KL. Hypertrophic cardiomyopathy and
sudden death. N Engl J Med 1988;318:1255–7.
24. Kron J, Oliver RP, Norsted S, Silka MJ. The automatic implantable
cardioverter-defibrillator in young patients. J Am Coll Cardiol 1990;
16:896–902.
25. Silka MJ, Kron J, Dunnigan A, Dick M. Sudden cardiac death and the
use of implantable cardioverter-defibrillators in pediatric patients.
Circulation 1993;87:800–7.
26. Primo J, Geelen P, Brugada J, et al. Hypertrophic cardiomyopathy:
role of the implantable cardioverter defibrillator. J Am Coll Cardiol
1998;31:1081–5.
27. Borgreffe M, Breithardt G. Is the implantable defibrillator indi-
cated in patients with hypertrophic cardiomyopathy and aborted
sudden death? J Am Coll Cardiol 1998;31:1086 – 8.
28. Zhu D, Sun H, Hill R, Roberts R. The value of electrophysiology
study and prophylactic implantation of cardioverter defibrillator in
patients with hypertrophic cardiomyopathy. PACE Pacing Clin Elec-
trophysiol 1998;21:299–302.
29. McKenna WJ, Oakley CM, Krikler DM, et al. Improved survival with
amiodarone in patients with hypertrophic cardiomyopathy and ven-
tricular tachycardia. Br Heart J 1985;53:412–6.
30. Fananapazir L, Leon MB, Bonow RO, Tracy CM, Cannon RO,
Epstein SE. Sudden death during empiric amiodarone therapy in
symptomatic hypertrophic cardiomyopathy. Am J Cardiol 1991;67:
169–74.
31. Elliott PM, Poloniecki J, Sharma S, Dickie S, McKenna WJ. Amio-
darone and sudden death in patients with hypertrophic cardiomyopa-
thy (abstr). Heart 1998;79:3.
1601JACC Vol. 33, No. 6, 1999 Elliott et al.
May 1999:1596–601 Sudden Death in Hypertrophic Cardiomyopathy
